Vietnam is investing heavily in advanced cancer treatment technologies as the country expands access to precision oncology services and modern radiotherapy infrastructure. Rising cancer incidence, increasing government healthcare investment and the adoption of next-generation treatment technologies are driving significant growth across the country's radiotherapy market.
While a comprehensive value for Vietnam's radiotherapy market is not publicly reported, industry analysis estimates the sector is currently worth US$60–80 million in 2025 and is expected to grow to US$95–125 million by 2030.
Supporting this outlook, Grand View Research estimates Vietnam's radiation oncology market generated US$18.1 million in 2024 and will reach US$30.9 million by 2030, highlighting the rapid expansion of cancer treatment technologies across the country.
Radiotherapy is one of the most important treatments in modern oncology, with international evidence indicating that around half of all cancer patients will require radiotherapy during the course of their treatment. Advances in imaging, treatment planning and precision radiation delivery are enabling clinicians to target tumours more accurately while reducing damage to surrounding healthy tissue.
Several factors are accelerating market growth across Vietnam:
- Rising incidence of breast, lung, liver, colorectal and cervical cancers.
- Government investment in expanding specialist cancer hospitals and regional oncology centres.
- Increasing installation of advanced linear accelerators (LINACs).
- Growing adoption of Intensity-Modulated Radiotherapy (IMRT), Image-Guided Radiotherapy (IGRT), Volumetric Modulated Arc Therapy (VMAT) and Stereotactic Body Radiotherapy (SBRT).
- Greater use of artificial intelligence for treatment planning, contouring and adaptive radiotherapy.
- Expansion of private oncology centres and multidisciplinary cancer services.
The radiotherapy market is also being supported by the rapid expansion of Vietnam's wider oncology sector. According to IMARC Group, the country's cancer diagnostics market reached US$887.2 million in 2025 and is forecast to grow to US$1.60 billion by 2034, reflecting increasing investment in early diagnosis, precision medicine and comprehensive cancer care.
Technological innovation continues to transform radiotherapy worldwide. Artificial intelligence is increasingly being used to automate treatment planning, improve tumour segmentation, optimise radiation dose delivery and monitor patient motion during treatment. These advances are reducing treatment times, improving accuracy and helping clinicians deliver more personalised cancer care.
Leading global manufacturers including Varian (Siemens Healthineers), Elekta, Accuray, GE HealthCare, Philips Healthcare, Canon Medical Systems, RaySearch Laboratories and IBA continue to introduce AI-enabled treatment planning systems, adaptive radiotherapy platforms and image-guided technologies that are shaping the future of radiation oncology.
As Vietnam continues to strengthen its national cancer strategy and invest in advanced healthcare infrastructure, radiotherapy is expected to become an increasingly important component of cancer diagnosis, treatment and long-term patient care. For suppliers of radiation therapy systems, treatment planning software, imaging technologies and oncology solutions, Vietnam represents one of Southeast Asia's most attractive long-term growth opportunities.